Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOV980)

Drug Name
GW1929 Drug Info
Synonyms GW 1929; GW-1929
Cross-matching ID
PubChem CID
6518171
ChEBI ID
CHEMBL434063
CAS Number
CAS 196808-24-9
TTD Drug ID
D04DYM
VARIDT Drug ID
DR00527

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.16 0.00e+0 34/36 (94.44%) MCM4;POLE2;PCNA;...
Allograft rejection 2.10 0.00e+0 32/38 (84.21%) HLA-DRB1;CD40;HLA-DRA;...
Intestinal immune network for IgA production 1.96 3.67e-3 38/48 (79.17%) HLA-DRB1;CD40;HLA-DRA;...
Systemic lupus erythematosus 1.92 8.25e-3 45/135 (33.33%) HLA-DRB1;CD40;C1R;...
Ribosome biogenesis in eukaryotes 1.87 1.10e-2 52/108 (48.15%) NXT1;GAR1;IMP3;...
Pentose and glucuronate interconversions 1.86 1.10e-2 17/34 (50%) UGT2B28;UGT2B15;UGT2B4;...
Type I diabetes mellitus 1.82 1.89e-2 38/43 (88.37%) HLA-DRB1;HLA-DRA;GZMB;...
Asthma 1.80 2.20e-2 25/31 (80.65%) HLA-DRB1;CD40;HLA-DRA;...
Autoimmune thyroid disease 1.79 2.08e-2 46/53 (86.79%) HLA-DRB1;CD40;HLA-DRA;...
Taurine and hypotaurine metabolism 1.78 1.98e-2 8/11 (72.73%) CSAD;GAD1;GAD2;...
Graft-versus-host disease 1.76 2.50e-2 32/42 (76.19%) HLA-DRB1;HLA-DRA;GZMB;...
Bile secretion 1.71 3.76e-2 68/90 (75.56%) CA2;UGT2B28;ADCY1;...
Drug metabolism 1.71 3.72e-2 78/151 (51.66%) UGT2B28;ADH5;RRM2;...
Cell cycle 1.70 3.69e-2 110/124 (88.71%) WEE1;MCM4;CCNB2;...
IL-17 signaling pathway 1.70 3.59e-2 84/94 (89.36%) S100A8;S100A9;CCL2;...
Pyrimidine metabolism 1.65 4.47e-2 40/56 (71.43%) NT5E;RRM2;TYMS;...
Ascorbate and aldarate metabolism 1.65 4.72e-2 15/30 (50%) UGT2B28;UGT2B15;UGT2B4
PPAR signaling pathway -1.87 2.37e-2 66/74 (89.19%) ME3;UBC;OLR1;...
AMPK signaling pathway -1.92 2.22e-2 106/120 (88.33%) PRKAB1;ULK1;PFKFB1;...
Steroid biosynthesis -2.36 0.00e+0 19/20 (95%) SQLE;SOAT1;EBP;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H